Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
M.D. Anderson Cancer Center
Endeavor Biomedicines, Inc.
University of California, San Francisco
Pfizer
Yale University
Memorial Sloan Kettering Cancer Center
Novartis